COR? YNEBA TERI UM PAR V UIM (CP) inhibits the growth and dissemination of a variety of experimental tumours (Halpern et al., 1966; Woodruff & Boak, 1966; Smith & Scott, 1972; Proctor et al., 1973; Sadler & Castro, 1976) . Given systematically, it causes non-specific stimulation of the reticulo-endothelial system (Halpern et al., 1963) which is regarded as the major mechanism of the anti-tumour action Milas & Scott, 1978) .
Previously our group has shown that i.v. CP causes thrombosis in hepatic, pulmonary and splenic blood vessels in mice, and it was concluded that CP induced disseminated intravascular coagulation (Lampert et al., 1977) . This assumption was supported by a subsequent study which showed prolonged thrombocytopenia after i.v. CP . The present investigations were designed to elucidate the kinetics and mechanisms of the CP-induced coagulopathy in itilice. (Dacie & Lewis, 1975) .
Fibrin/fibrinogen degradation products (FDP) were determined by the staphylococcal clumping test (Hawiger et al., 1970) .
Platelet volume distribution was evaluated electronically by a Coulter Counter ZBI in connection with a Channelyser.
Platelet turnover and distribution.-Blood from 45 age-and sex-matched syngeneic donor mice was mixed 1 in 5 with acidcitrate-dextrose (ACD). Platelets were separated by differential centrifugation, labelled with 51chromium (Dacie & Lewis, 1975) immediately before CP at a. dose of 100 Mug in 0-2 ml given i.p. and contmiued twice daily for 2 days. Thereafter a single daily dose of 50 ,g was given.
Statistics.-Sets of results were compared by the t test for 2 samples.
RESULTS
Intravenous CP.-350 ug of CP injected i.v. into C57BL mice caused a coagulopathy (Table I) characterized by severe thrombocytopenia, a significant decrease in plasma fibrinogen, and a significant increase of serum fibrin/fibrinogen degradation products (FDP). There were minor changes in the prothrombin time and activated partial thromboplastin time.
Changes were greatest on the 9th day after CP, with recovery by Day 21. There was an accompanying anaemia, and on the 7th day many fragmented red cells were seen on the blood films. On the 7th day the mean platelet corpuscular volume was significantly greater than the controls (8.20 + 0-68 fl compared to 6-54 + 0-55 fl, P <0.05).
The effects of 350 Mg of CP injected i.v. were compared with those of 70 ug. The changes in spleen weight and number of peripheral-blood platelets are shown in Fig. 1 . Liver weight followed the same trend as the spleen. Changes were dose dependent, and the development of hepatosplenomegaly correlated with thrombocytopenia.
BALB/c mice given 350 Mg of CP i.v. also developed marked hepatosplenomegaly, and experienced a severe coagulopathy identical to that in C57BL mice.
I.p. and s.c. CP (Table II) . Significance against control: *P < 0-01, **P < 0-001. 
Ir
,injection had little effect on the measured variables. Platelet kinetics and distribution. Platelet kinetics are shown in Fig. 2 Significance against control: *P < 0-01, **P < 0-001.
activity in their spleens than did controls. There was a minor non-significant rise in radioactivity in livers of mice 2 days after CP which decreased by Day 7. Lung and kidney were also examined and contained little radioactivity. Treatment.-Various treatments were given in an attempt to alter the coagulopathy after i.v. CP (Table IV) . Splenectomy failed to protect against coagulopathy. EACA-treated animals had enhanced coagulopathy, with lowered fibrinogen and increased thrombosis on histological examination. Indomethacin totally abrogated the coagulation changes. Splenectomy, EACA and indomethacin treatments in normal mice had no effect on the measured variables. DISCUSSION CP has been shown to decrease the number of peripheral-blood platelets and we have now demonstrated changes in the plasmatic coagulation system which parallel this thrombocytopenia. There was a marked decrease of plasma fibrinogen, an increase of serum fibrin/fibrinogen degradation products (FDP) and minor changes in the prothrombin and activated partial thromboplastin times. These findings indicate disseminated intravascular coagulation (DIC). The concomitant appearance of many fragmented red cells associated with anaemia suggests microangiopathic haemolytic anaemia, a syndrome considered to be a consequence of intravascular fibrin deposition (Bull & Kuhn, 1970) . This explanation of the anaemia following CP would be additional to mechanisms previously described, i.e. enhanced phagocytosis and destruction of erythrocytes by the CP-stimulated RES (Cox & Keast, 1974; McBride et al., 1974) and CPinduced autoantibody against red cells (McCracken et al., 1971) .
There was no evidence of failure of platelet production, since there was no marrow toxicity (unpublished data) and because the appearance of larger platelets indicated young platelets entering the circulation. This suggested the cause of the thrombocytopenia to be increased peripheral platelet destruction as was confirmed by platelet turnover studies. We considered that the hepatomegaly and splenomegaly might be the sites of this increased platelet destruction. When allowance was made for the 2-fold increase in liver weight and 3-fold increase in spleen weight by the 7th day after i.v. CP, the relative uptake of radioactive platelets by these organs was less than the controls. We found no evidence of active sequestration or passive platelet pooling in the liver, spleen, lung or kidney, and splenectomy failed to prevent any of the coagulation changes. This is surprising since Lampert et al. (1977) described thrombi in the liver and spleen of CPtreated mice, but the discrepancy may be explained if the thrombi were both precipitated and removed simultaneously, a phenomenon well known in experimental animals after endotoxin injection (Theiss et al., 1975) . Accelerated proteolytic activity is part of the pathophysiology of intravascular coagulation, and its occurrence is supported by the observation that animals treated with the anti-fibrinolytic agent EACA, following injection of CP, had enhancement of the coagulopathy with increased thrombosis. The correlation between hepato-splenomegaly and coagulation changes suggests that these two phenomena might be mediated by the same mechanism. The organomegaly is associated with an increase in tissue macrophages (McBride et al., 1974; Warr & Sljivic, 1974; Maruyama & Coleman, 1978) and phagocytic activity (Halpern et al., 1963; Adlam & Scott, 1973) . Activated macrophages produce various unstable metabolites of arachidonic acid (Brune et al., 1978) including thromboxane A2. This factor can cause intravascular platelet aggregation with subsequent activation of the coagulation system, and its release from macrophages can be inhibited by indomethacin (Brune et al., 1978) . Indomethacin treatment of animals following i.v. injection of CP completely prevented the coagulopathy, indicating that enhanced prostaglandin biosynthesis may mediate the coagulation changes.
When the route of administration was altered from i.v., we found that i.p. injection of 350 tg of CP caused similar, but less pronounced, coagulation changes, and s.c. injection had no effect. S.c. CP at this dose has little, if any, anti-tumour action (Sadler & Castro, 1976) suggesting that CP given s.c. does not reach the target macrophages. BALB/c mice injected with CP also developed a severe coagulopathy, demonstrating that this CP effect is not strain specific.
In summary, administration of CP induces a coagulopathy in mice as a consequence of intravascular coagulation with fibrinolysis. It appears that clot-promoting material, possibly derived from the macrophages, initiates this phenomenon. Increased fibrinolytic activity has been found in cancer patients treated with CP (Cederholm-Williams et al., 1978) indicating that our findings might be clinically relevant.
